Adjuvant chemotherapy

Uschi Hofmann, Fiona Collinson, Peter Hall, Mike Braun and Daniel Swinson

in Colorectal Cancer

Published on behalf of Oxford University Press

ISBN: 9780199590209
Published online May 2012 | e-ISBN: 9780191739675 | DOI:

Series: Oxford Oncology Library

Adjuvant chemotherapy

Show Summary Details


• Adjuvant single agent fluoropyrimidine (Fu) reduces the relative risk of death following potentially curative surgery by 20–30%. Addition of oxaliplatin reduces relative risk by a further 15% • The risk reduction is proportional to the absolute risk so the higher the risk the greater the benefit. Thus adjuvant chemotherapy only achieves a meaningful benefit for patients with stage III and high risk stage II disease • The benefit from single agent Fu does not diminish with age although data is limited for patients over the age of 80. In contrast the benefit of the addition of oxaliplatin is questionable over the age of 70 • Discussions with patients should include an estimate of the chances of benefit with single agent and combination adjuvant chemotherapy.

Chapter.  3448 words. 

Subjects: Medical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.